コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 B lymphocytes that are deleted by anti-CD20 cotherapy.
2 4%) for current users of coxibs without such cotherapy.
3 3 (24.7%) prescribed an NS-NSAID without GPA cotherapy.
4 , 347 (18.9%) prescribed dual coxib plus GPA cotherapy, 173 (9.4%) prescribed a nonselective NSAID (N
7 urrent users of NSAIDs with gastroprotective cotherapy and 40% (23%-54%) for current users of coxibs
9 hrombotic without the requirement of aspirin cotherapy and may provide benefits even to the aspirin-n
11 bed a nonselective NSAID (NS-NSAID) plus GPA cotherapy, and 453 (24.7%) prescribed an NS-NSAID withou
12 iatal tissue analyses showed that nalbuphine cotherapy blocks several molecular correlates of LID, in
14 e-2 inhibitors for patients who need aspirin cotherapy for the prevention of arterial thrombus format
15 were significantly higher for the olanzapine cotherapy group included somnolence, dry mouth, weight g
16 r remission rates in the MTX and other DMARD cotherapy groups (8% and 5%, respectively) as in the mon
17 odel the response in the MTX and other DMARD cotherapy groups relative to the monotherapy group separ
18 ent users of NSAIDs with no gastroprotective cotherapy had an adjusted incidence of peptic ulcer hosp
20 score of > or = 20 at baseline), olanzapine cotherapy improved HAMD-21 scores by 10.31 points compar
23 ximab guidelines suggest that MTX be used as cotherapy, in clinical practice, both monotherapy and co
25 alproate therapy, were randomized to receive cotherapy (olanzapine + mood-stabilizer) or monotherapy
26 NSAIDs combined with recommended anti-ulcer cotherapy or use of a selective cyclooxygenase 2-inhibit
28 strointestinal complications, recognition of cotherapies that could reduce NSAID toxicity, and, most
29 e in diagnostics and as leads for anticancer cotherapies, used as enhancements of alkylating agents i
34 MTX and, to a lesser extent, other DMARDs as cotherapy with etanercept was associated with a higher l
35 ieving a higher EULAR response category with cotherapy with MTX (odds ratio [OR] 2.0, 95% confidence
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。